Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer

被引:0
作者
Dirk Müller
Marion Danner
Rita Schmutzler
Christoph Engel
Kirsten Wassermann
Björn Stollenwerk
Stephanie Stock
Kerstin Rhiem
机构
[1] The University Hospital of Cologne (AöR),Institute for Health Economics and Clinical Epidemiology
[2] University Hospital Cologne,Center for Hereditary Breast and Ovarian Cancer
[3] University of Leipzig,Institute for Medical Informatics, Statistics and Epidemiology
[4] German Research Center for Environmental Health,Institute of Health Economics and Health Care Management, Helmholtz Zentrum München
来源
The European Journal of Health Economics | 2019年 / 20卷
关键词
Cost-effectiveness; Economic modeling; Genetic testing; Breast cancer; Risk-reducing surgery; BRCA; I110 (Analysis of Health Care Markets);
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:739 / 750
页数:11
相关论文
共 448 条
[11]  
Jervis S(2012)Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial Lancet Oncol. 13 412-975
[12]  
van Leeuwen FE(2010)Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality JAMA 304 967-1062
[13]  
Milne RL(2012)Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany BMC Cancer 28 317-2709
[14]  
Andrieu N(2004)Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group J. Clin. Oncol. 22 1055-822
[15]  
Goldgar DE(2010)Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer Ann. Surg. Oncol 17 2702-749
[16]  
Terry MB(2013)EMBRACE.:Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE J. Natl. Cancer Inst. 105 812-184
[17]  
Rookus MA(2005)A national catalog of preference-based scores for chronic conditions in the United States Med. Care 43 736-292
[18]  
Easton DF(2010)Breast cancer-related preferences among women with and without BRCA mutations Breast Cancer Res. Treat. 119 177-566
[19]  
Antoniou AC(1999)The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations Cancer J. Sci. Am. 5 283-220
[20]  
McGuffog L(2010)Health-state utility values in breast cancer Expert Rev. Pharmacoecon. Outcomes Res. 10 553-974